{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:29:53Z","timestamp":1794274193909,"version":"4.9.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Programmed cell death ligand 1 (PD-L1) is cell surface glycoprotein that regulates the cellular immune response and serves as a targetable immune checkpoint molecule. Previous studies have demonstrated consistent expression of PD-L1 by Reed-Sternberg (RS) cells, as well as nonmalignant tumor-infiltrating macrophages in classic Hodgkin lymphoma (CHL). Bone marrow involvement by CHL is uncommon, being present in 5% to 10% of cases, but indicates Ann Arbor stage IV disease. Given the mixed inflammatory infiltrate that characterizes CHL, detection of RS cells in small bone marrow biopsies may be difficult. We sought to investigate the diagnostic utility of PD-L1 expression in staging bone marrow biopsies from patients with newly diagnosed CHL. Forty-four staging bone marrow biopsies from patients with newly diagnosed CHL were examined for PD-L1 expression by immunohistochemistry. Eight bone marrow biopsies were positive for involvement by CHL (8\/44, 18%) and all were positive for PD-L1 (8\/8, 100%), including a case that was originally nondiagnostic. Membranous PD-L1 expression was restricted to RS cells and the adjacent nontumor inflammatory cells admixed within areas of fibrosis. Uninvolved bone marrow biopsies and normal-appearing marrow in cases positive for CHL were negative for PD-L1. In comparison, bone marrow biopsies with myelofibrosis caused by myeloproliferative or myelodysplastic disorders were negative for significant PD-L1 staining. PD-L1 expression in RS cells and surrounding inflammatory cells is a sensitive marker for bone marrow involvement by CHL. In cases where RS cells are infrequent, PD-L1 staining in regions of fibrosis may serve as a useful diagnostic clue to involvement by CHL.<\/jats:p>","DOI":"10.1097\/pai.0000000000000628","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T04:47:50Z","timestamp":1513918070000},"page":"356-363","source":"Crossref","is-referenced-by-count":5,"title":["PD-L1 Immunohistochemistry Highlights Bone Marrow Involvement by Classic Hodgkin Lymphoma in Staging Biopsies: Implications for Diagnosis and Tumor Microenvironment Alterations"],"prefix":"10.1097","volume":"27","author":[{"given":"Wei","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma","volume":"104","author":"Juszczynski","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1365-2141.2002.03842.x","article-title":"The value of bone marrow examination in the staging of Hodgkin\u2019s lymphoma: a review of 955 cases seen in a regional cancer centre","volume":"119","author":"Howell","year":"2002","journal-title":"Br J Haematol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3816\/CLM.2004.n.010","article-title":"A large-scale study of bone marrow involvement in patients with Hodgkin\u2019s lymphoma","volume":"5","author":"Levis","year":"2004","journal-title":"Clin Lymphoma"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Hoppe","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"59976","DOI":"10.18632\/oncotarget.11045","article-title":"PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00277-016-2915-4","article-title":"Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms","volume":"96","author":"Choi","year":"2017","journal-title":"Ann Hematol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk Res"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","article-title":"Programmed Death Ligand-1 (PD-L1) Expression in the programmed death receptor-1 (PD-1)\/PD-L1 blockade: a key player against various cancers","volume":"141","author":"Guan","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.mayocp.2011.08.002","article-title":"Predictive parameters for a diagnostic bone marrow biopsy specimen in the work-up of fever of unknown origin","volume":"87","author":"Ben-Baruch","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/imj.12443","article-title":"Diagnostic utility of bone marrow examination for the assessment of patients with fever of unknown origin: a 10-year single-centre experience","volume":"44","author":"Labrador","year":"2014","journal-title":"Intern Med J"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Applied Immunohistochemistry &amp; Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00129039-201905000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T19:10:29Z","timestamp":1695409829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00129039-201905000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pai.0000000000000628","relation":{},"ISSN":["1541-2016"],"issn-type":[{"value":"1541-2016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}